08:24 AM EDT, 08/26/2025 (MT Newswires) -- Virax Biolabs ( VRAX ) said Tuesday it signed a research services agreement with Emory University's Adjust Center to conduct clinical studies of ViraxImmune for immune profiling in post-viral syndromes, starting with long COVID.

Emory's Laboratory for Innovative Assay Development will recruit patients, conduct testing, and generate clinical data to support Virax's regulatory submissions and potential commercial rollout, the company said.

Virax also said it is preparing for a pre-submission meeting with the US Food and Drug Administration in September to seek feedback on intended use and trial design for ViraxImmune.

ViraxImmune is a proprietary T cell testing technology aimed at providing a broader view of immune health than traditional antibody testing, it said.

Shares of the company were up 2.4% in recent Tuesday premarket activity.